Generic filters
Filter by content type
Taxonomy terms

EIGR – Eiger BioPharmaceuticals Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 31.8

Low: 21

High: 57

Total Analysts: 4

Company Profile

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). It is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The Company is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan